{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:13:57Z","timestamp":1791108837279,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.leukres.2014.02.011","type":"journal-article","created":{"date-parts":[[2014,3,2]],"date-time":"2014-03-02T15:32:34Z","timestamp":1393774354000},"page":"594-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"38","author":[{"given":"P.K.","family":"Estrada-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"G\u00f3mez-Ceja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ch\u00e1vez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Meill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"S\u00e1nchez-Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7453-1125","authenticated-orcid":false,"given":"E.","family":"Flores-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.02.011_bib0005","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.02.011_bib0015","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.011_bib0020","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.02.011_bib0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"J\u00f6nsson","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.02.011_bib0030","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.011_bib0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","article-title":"Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib","volume":"94","author":"O'Sullivan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.leukres.2014.02.011_bib0040","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response","volume":"82","author":"Osorio","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.02.011_bib0045","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.02.011_bib0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro","volume":"40","author":"Fierro","year":"2007","journal-title":"Cell Prolif"},{"key":"10.1016\/j.leukres.2014.02.011_bib0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","article-title":"Effects of imatinib mesylate in osteoblastogenesis","volume":"37","author":"Tibullo","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2014.02.011_bib0060","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0003","article-title":"Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion","volume":"48","author":"Fitter","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.leukres.2014.02.011_bib0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.leukres.2004.06.011","article-title":"Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization","volume":"29","author":"Flores-Figueroa","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14653240802582075","article-title":"Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression","volume":"11","author":"Montesinos","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.leukres.2014.02.011_bib0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.leukres.2005.06.028","article-title":"Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures","volume":"30","author":"Ch\u00e1vez-Gonz\u00e1lez","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0085","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.leukres.2008.02.013","article-title":"Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells","volume":"32","author":"Flores-Figueroa","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.leukres.2014.02.011_bib0095","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.leukres.2006.04.013","article-title":"Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion","volume":"30","author":"Jootar","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0100","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.leukres.2005.12.010","article-title":"Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia","volume":"30","author":"Zhao","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0100-879X2006005000055","article-title":"Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant","volume":"40","author":"Carrara","year":"2007","journal-title":"Braz J Med Biol Res."},{"key":"10.1016\/j.leukres.2014.02.011_bib0110","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.leukres.2010.09.019","article-title":"Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: effect of vascular endothelial growth factor on development of the microenvironment","volume":"35","author":"Shirasaki","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0115","doi-asserted-by":"crossref","first-page":"e38954","DOI":"10.1371\/journal.pone.0038954","article-title":"Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells","volume":"7","author":"Rosu-Myles","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.leukres.2014.02.011_bib0120","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.ejca.2011.11.003","article-title":"The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia","volume":"48","author":"Zhao","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2014.02.011_bib0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cyto.b.20118","article-title":"Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow","volume":"70","author":"Jones","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.leukres.2014.02.011_bib0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11670-011-0043-1","article-title":"Factors affecting mesenchymal stromal cells yield from bone marrow aspiration","volume":"23","author":"Li","year":"2011","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.leukres.2014.02.011_bib0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.leukres.2014.02.011_bib0140","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.011_bib0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00774-011-0323-3","article-title":"Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro","volume":"3","author":"J\u00f6nsson","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.leukres.2014.02.011_bib0150","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.011_bib0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1358\/dot.2013.49.3.1937430","article-title":"The role of imatinib in the treatment of pulmonary hypertension","volume":"49","author":"Mucke","year":"2013","journal-title":"Drugs Today"},{"key":"10.1016\/j.leukres.2014.02.011_bib0160","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameter in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit."},{"key":"10.1016\/j.leukres.2014.02.011_bib0165","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.02.011_bib0175","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/labinvest.2012.93","article-title":"Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow","volume":"92","author":"Flores-Figueroa","year":"2012","journal-title":"Lab Investig"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614000605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:53:22Z","timestamp":1565218402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614000605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0145212614000605"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.02.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}